866-997-4948(US-Canada Toll Free)

Retinoblastoma - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Dec 2013

Category :

Oncology

No. of Pages : 43 Pages


Global Markets Directs, \'Retinoblastoma Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Retinoblastoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinoblastoma. Retinoblastoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Retinoblastoma.
  • A review of the Retinoblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Retinoblastoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Retinoblastoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Retinoblastoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Retinoblastoma Overview 6
Therapeutics Development 7
Pipeline Products for Retinoblastoma - Overview 7
Pipeline Products for Retinoblastoma - Comparative Analysis 8
Retinoblastoma - Therapeutics under Development by Companies 9
Retinoblastoma - Therapeutics under Investigation by Universities/Institutes 10
Retinoblastoma - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Retinoblastoma - Products under Development by Companies 13
Retinoblastoma - Products under Investigation by Universities/Institutes 14
Retinoblastoma - Companies Involved in Therapeutics Development 15
BioLineRx, Ltd. 15
Neotropix, Inc. 16
Icon Bioscience, Inc. 17
RXi Pharmaceuticals Corporation 18
Retinoblastoma - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Assessment by Therapeutic Class 28
Drug Profiles 30
NTX-010 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
BL-8040 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
melphalan - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Nutlin-3 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Drug for Retinoblastoma - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Retinoblastoma - Recent Pipeline Updates 38
Retinoblastoma - Product Development Milestones 40
Featured News & Press Releases 40
Mar 08, 2013: Cellceutix Announces Positive Preclinical Trial Data Of Kevetrin In Retinoblastoma 40
Jan 03, 2013: Icon\'s Melphalan Intraocular Injection Receives US Orphan Drug Designation For Treatment Of Retinoblastoma 40

Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43

List of Table


Number of Products under Development for Retinoblastoma, H2 2013 7
Number of Products under Development for Retinoblastoma - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
Products under Investigation by Universities/Institutes, H2 2013 14
Retinoblastoma - Pipeline by BioLineRx, Ltd., H2 2013 15
Retinoblastoma - Pipeline by Neotropix, Inc., H2 2013 16
Retinoblastoma - Pipeline by Icon Bioscience, Inc., H2 2013 17
Retinoblastoma - Pipeline by RXi Pharmaceuticals Corporation, H2 2013 18
Assessment by Monotherapy Products, H2 2013 19
Number of Products by Stage and Target, H2 2013 21
Number of Products by Stage and Mechanism of Action, H2 2013 23
Number of Products by Stage and Route of Administration, H2 2013 25
Number of Products by Stage and Molecule Type, H2 2013 27
Number of Products by Stage and Therapeutic Class, H2 2013 29
Retinoblastoma Therapeutics - Recent Pipeline Updates, H2 2013 38

List of Chart


Number of Products under Development for Retinoblastoma, H2 2013 7
Number of Products under Development for Retinoblastoma - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Early Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 19
Number of Products by Top 10 Target, H2 2013 20
Number of Products by Stage and Top 10 Target, H2 2013 21
Number of Products by Top 10 Mechanism of Action, H2 2013 22
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 23
Number of Products by Top 10 Route of Administration, H2 2013 24
Number of Products by Stage and Top 10 Route of Administration, H2 2013 25
Number of Products by Top 10 Molecule Type, H2 2013 26
Number of Products by Stage and Top 10 Molecule Type, H2 2013 27
Number of Products by Top 10 Therapeutic Class, H2 2013 28
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 29

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *